

# Primary Sclerosing Cholangitis Treatment Market Size, Trends, Analysis, and Outlook By Type (Liver Transplantation Operation, UDCA Drugs, PSC Drugs), By Application (Hospital, Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/P8867E1A27B1EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: P8867E1A27B1EN

## Abstracts

The global Primary Sclerosing Cholangitis Treatment market size is poised to register 7.34% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Primary Sclerosing Cholangitis Treatment market By Type (Liver Transplantation Operation, UDCA Drugs, PSC Drugs), By Application (Hospital, Clinics, Others).

The future of primary sclerosing cholangitis (PSC) treatment is shaped by advancements in understanding disease pathogenesis, targeted therapies, and liver transplantation techniques aimed at improving outcomes and quality of life for patients with this chronic liver condition. Key trends include the development of disease-modifying therapies targeting immune dysregulation, bile duct inflammation, and fibrosis progression in PSC, including anti-inflammatory agents, immunomodulators, and antifibrotic drugs. Additionally, there's growing interest in combination therapy approaches and biologic agents, such as anti-TNF antibodies and anti-integrin inhibitors, to address the multifactorial nature of PSC and improve treatment response rates. Moreover, advancements in non-invasive diagnostic methods, such as magnetic resonance imaging (MRI) and serum biomarkers, are enabling early detection of PSC and monitoring of disease progression, facilitating timely intervention and personalized treatment strategies for patients..

Primary Sclerosing Cholangitis Treatment Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Primary Sclerosing Cholangitis Treatment market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Primary Sclerosing Cholangitis Treatment survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Primary Sclerosing Cholangitis Treatment industry.

Key market trends defining the global Primary Sclerosing Cholangitis Treatment demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Primary Sclerosing Cholangitis Treatment Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Primary Sclerosing Cholangitis Treatment industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Primary Sclerosing Cholangitis Treatment companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Primary Sclerosing Cholangitis Treatment industry

Leading Primary Sclerosing Cholangitis Treatment companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Primary Sclerosing Cholangitis Treatment companies.

## Primary Sclerosing Cholangitis Treatment Market Study- Strategic Analysis Review

The Primary Sclerosing Cholangitis Treatment market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

## Primary Sclerosing Cholangitis Treatment Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Primary Sclerosing Cholangitis Treatment industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

## Primary Sclerosing Cholangitis Treatment Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

## North America Primary Sclerosing Cholangitis Treatment Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Primary Sclerosing Cholangitis Treatment market segments. Similarly, Strong end-user demand is encouraging Canadian Primary Sclerosing Cholangitis Treatment companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Primary Sclerosing Cholangitis Treatment market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Primary Sclerosing Cholangitis Treatment Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Primary Sclerosing Cholangitis Treatment industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Primary Sclerosing Cholangitis Treatment market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Primary Sclerosing Cholangitis Treatment in Asia Pacific. In particular, China, India, and South East Asian Primary Sclerosing Cholangitis Treatment markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in

the region.

### Latin America Primary Sclerosing Cholangitis Treatment Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

### Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Primary Sclerosing Cholangitis Treatment market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Primary Sclerosing Cholangitis Treatment.

### Primary Sclerosing Cholangitis Treatment Market Company Profiles

The global Primary Sclerosing Cholangitis Treatment market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Acorda Therapeutics, Allergan, Bruschettini, Conatus Pharmaceuticals, Daewoong Pharmaceutical, Dr. Falk Pharma, Durect Corp, Epic Pharma, Gilead Sciences Inc, Glenmark, Grindeks, Impax Laboratories, Intercept Pharmaceuticals, Lannett, Mitsubishi Tanabe Pharma, Mylan N.V., NGM Biopharmaceuticals, Shanghai Pharma, Shenzhen HighTide Biopharmaceuticals, Shire Plc, Sirnaomics, Teva Pharmaceuticals.

### Recent Primary Sclerosing Cholangitis Treatment Market Developments

The global Primary Sclerosing Cholangitis Treatment market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

### Primary Sclerosing Cholangitis Treatment Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

## By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

## By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

## By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

## Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

## Companies

Acorda Therapeutics

Allergan

Bruschettini

Conatus Pharmaceuticals

Daewoong Pharmaceutical

Dr. Falk Pharma

Durect Corp

Epic Pharma

Gilead Sciences Inc

Glenmark

Grindeks

Impax Laboratories



Intercept Pharmaceuticals

Lannett

Mitsubishi Tanabe Pharma

Mylan N.V.

NGM Biopharmaceuticals

Shanghai Pharma

Shenzhen HighTide Biopharmaceuticals

Shire Plc

Sirnaomics

Teva Pharmaceuticals

Formats Available: Excel, PDF, and PPT

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Primary Sclerosing Cholangitis Treatment Market Overview and Key Findings, 2024
- 1.2 Primary Sclerosing Cholangitis Treatment Market Size and Growth Outlook, 2021-2030
- 1.3 Primary Sclerosing Cholangitis Treatment Market Growth Opportunities to 2030
- 1.4 Key Primary Sclerosing Cholangitis Treatment Market Trends and Challenges
  - 1.4.1 Primary Sclerosing Cholangitis Treatment Market Drivers and Trends
  - 1.4.2 Primary Sclerosing Cholangitis Treatment Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Primary Sclerosing Cholangitis Treatment Companies

### **2. PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET SIZE OUTLOOK TO 2030**

- 2.1 Primary Sclerosing Cholangitis Treatment Market Size Outlook, USD Million, 2021-2030
- 2.2 Primary Sclerosing Cholangitis Treatment Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### **3. PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

#### 4.1 Market Segmentation and Scope

#### 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

##### By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

##### By Display

Color Ultrasound

B/W Ultrasound

##### By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

##### By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

##### By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

#### 4.3 Growth Prospects and Niche Opportunities, 2023- 2030

#### 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

### 5. REGION-WISE MARKET OUTLOOK TO 2030

#### 5.1 Key Findings for Asia Pacific Primary Sclerosing Cholangitis Treatment Market, 2025

#### 5.2 Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Outlook by Type, 2021- 2030

#### 5.3 Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Outlook by Application, 2021- 2030

- 5.4 Key Findings for Europe Primary Sclerosing Cholangitis Treatment Market, 2025
- 5.5 Europe Primary Sclerosing Cholangitis Treatment Market Size Outlook by Type, 2021- 2030
- 5.6 Europe Primary Sclerosing Cholangitis Treatment Market Size Outlook by Application, 2021- 2030
- 5.7 Key Findings for North America Primary Sclerosing Cholangitis Treatment Market, 2025
- 5.8 North America Primary Sclerosing Cholangitis Treatment Market Size Outlook by Type, 2021- 2030
- 5.9 North America Primary Sclerosing Cholangitis Treatment Market Size Outlook by Application, 2021- 2030
- 5.10 Key Findings for South America Primary Sclerosing Cholangitis Treatment Market, 2025
- 5.11 South America Pacific Primary Sclerosing Cholangitis Treatment Market Size Outlook by Type, 2021- 2030
- 5.12 South America Primary Sclerosing Cholangitis Treatment Market Size Outlook by Application, 2021- 2030
- 5.13 Key Findings for Middle East and Africa Primary Sclerosing Cholangitis Treatment Market, 2025
- 5.14 Middle East Africa Primary Sclerosing Cholangitis Treatment Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa Primary Sclerosing Cholangitis Treatment Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

- 6.1 US Primary Sclerosing Cholangitis Treatment Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts

- 6.10 France Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities

6.39 Middle East Market Size Outlook and Revenue Growth Forecasts

6.40 Middle East Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities

6.41 Africa Market Size Outlook and Revenue Growth Forecasts

6.42 Africa Primary Sclerosing Cholangitis Treatment Industry Drivers and Opportunities

## **7. PRIMARY SCLEROSING CHOLANGITIS TREATMENT MARKET OUTLOOK ACROSS SCENARIOS**

7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. PRIMARY SCLEROSING CHOLANGITIS TREATMENT COMPANY PROFILES**

8.1 Profiles of Leading Primary Sclerosing Cholangitis Treatment Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Acorda Therapeutics

Allergan

Bruschettini

Conatus Pharmaceuticals

Daewoong Pharmaceutical

Dr. Falk Pharma

Direct Corp

Epic Pharma

Gilead Sciences Inc

Glenmark

Grindeks

Impax Laboratories

Intercept Pharmaceuticals

Lannett

Mitsubishi Tanabe Pharma

Mylan N.V.

NGM Biopharmaceuticals

Shanghai Pharma

Shenzhen HighTide Biopharmaceuticals

Shire Plc

Sirnaomics  
Teva Pharmaceuticals

## **9. APPENDIX**

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

## I would like to order

Product name: Primary Sclerosing Cholangitis Treatment Market Size, Trends, Analysis, and Outlook By Type (Liver Transplantation Operation, UDCA Drugs, PSC Drugs), By Application (Hospital, Clinics, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/P8867E1A27B1EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8867E1A27B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970